Pegfilgrastim biosimilar - Cinfa Biotech

Drug Profile

Pegfilgrastim biosimilar - Cinfa Biotech

Alternative Names: B 12019; Pegylated granulocyte colony stimulating factor - Cinfa Biotech

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cinfa Biotech
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Neutropenia

Most Recent Events

  • 04 Oct 2017 Preregistration for Neutropenia in European Union (SC)
  • 08 Sep 2017 Pharmacodynamics and Adverse event data from a phase I trial in Neutropenia (In volunteers) presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 01 May 2017 Cinfa Biotech completes a phase I trial in Healthy volunteers in Germany (SC) (NCT02912377)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top